Management team

Michael H. Tardugno

President and Chief Executive Officer

Mr. Tardugno's career has been exclusively focused in the healthcare and brings over 29 years of experience in the pharmaceutical and medical device industries to Celsion. He has held positions of increasing responsibility in general management, operations, and product and technology development. Prior to joining the company in 2007, Mr. Tardugno served as Senior Vice President and General Manager of Mylan Technologies Inc., a subsidiary of Mylan Laboratories, a transdermal delivery system and medical components company. Before Mylan, he was a founding member of management and Executive Vice President of Songbird Hearing, Inc, a privately held start-up company. Before Songbird, he held the positions of Senior Vice President of Technical Operations, World Wide for the ConvaTec division of Bristol-Myers Squibb, and World Wide Vice President of Technology Development and Manufacturing for Bausch & Lomb. Mr. Tardugno began his career in 1977 with Abbott Laboratories where he held positions in pharmaceutical operations and as plant manager for the company's Ross Laboratories Division nutritional business. Mr. Tardugno holds a B.S. in Biology with Chemistry concentration from St. Bonaventure University and attended the Harvard Business School executive program.

Nicholas Borys M.D.

Vice President and Chief Medical Officer

Nicholas Borys, M.D. joined Celsion on October 1, 2007 as Vice President and Chief Medical Officer. In this position Dr. Borys manages the clinical development program for Celsion. Dr. Borys, who was most recently Chief Medical Officer at Molecular Insight Pharmaceuticals, Inc, has accumulated extensive experience in all phases of pharmaceutical development with a focus in oncology while holding increasingly senior positions at Cytogen Corporation, Anthra Pharmaceuticals, Inc., Amersham Healthcare, Inc. and Hoffmann La-Roche Inc. Dr. Borys attended Rutgers University and holds an M.D. Degree from American University of the Caribbean.

Robert A. Reed, PhD.

Executive Director, CMC and Technological Operations

Robert A. Reed, Ph.D. joined Celsion on May 11, 2009 as Executive Director, CMC and Technological Operations. In this position Dr. Reed oversees the CMC, QA and Technical Operations functions for Celsion. He most recently was Vice President, Pharmaceutical Operations at XenoPort, Inc., has 18+ years of experience & responsibility across XenoPort, Inc, Merck & Company, Inc., and The Liposome Company, Inc., with extensive scientific and regulatory experience in the design and development of pharmaceutical products. He holds a Ph.D. in Analytical Chemistry from The University of North Carolina at Chapel Hill and was the recipient of a 3 year NIH Postdoctoral Individual Award at Princeton University.

Raj Prabhakar

Executive Director, Strategic Planning & Business Development

Raj Prabhakar joined Celsion in January 2004 and served as Director of Program Management leading the liver cancer program from preclinical stage through launch of the global Phase III HCC study. He was promoted to his current position of Executive Director of Strategic Planning & Business Development in January 2009, after serving as Senior Director of Strategic Planning and Business Development in December 2007. Raj currently heads up out-licensing and business development activities for Celsion, including managing the collaboration relationship with Yakult Honsha Co., Ltd. for the Japan Territory. Raj has over 8 years of biomedical industry experience including Celsion, Protiveris (proteomics), Osiris Therapeutics (stem cells) and Harvard Medical School (orthopedic implants). Prior to receiving his M.B.A., Raj held analyst and associate positions for four years in several finance, venture capital and private equity firms. In addition to 12 years of experience, Raj holds an M.B.A. from the Harvard Business School and dual B.S. degrees from MIT in biology and mechanical engineering.

Timothy J. Tumminello

Controller and Interim Chief Accounting Officer

Timothy J. Tumminello joined Celsion as Assistant Controller in April, 2009 and was appointed the Company's Controller and Interim Chief Accounting Officer on January 6, 2010. Prior to Mr. Tumminello's employment with the Company, he was employed by IC Isaacs & Company, Inc., from May 1997 to January 2009 and held various positions during his tenure that included serving as Vice President, Controller and Principal Financial Officer at the time of his departure in 2009. Mr. Tumminello was employed in the Baltimore, Maryland office of Deloitte & Touche LLP from January 1991 until May 1997. Mr. Tumminello is a certified public accountant.